GLP-1 agonists · Heretic

Short answer

GLP-1 receptor agonists are incretin-mimicking drugs with large randomized-trial evidence for weight loss: semaglutide about 15%, tirzepatide about 21%, and retatrutide up to about 30% in phase 3. Semaglutide also cut major cardiovascular events 20% in the 17,604-person SELECT trial. The caveats are lean-mass loss (25-39% of weight lost), rapid regain after stopping, and unproven claims such as slowed epigenetic aging, which rest on one small post-hoc analysis.

Summary drafted from this entry’s sources; editorial review pending.

01Key questions

Do GLP-1 drugs work for weight loss?

Yes, in large randomized trials: semaglutide produced 14.9% weight loss at 68 weeks in STEP 1, tirzepatide 20.9% at 72 weeks in SURMOUNT-1, and retatrutide up to 30.3% at 104 weeks in TRIUMPH-1.¹³

Do GLP-1 drugs protect the heart?

Semaglutide does: the SELECT trial in 17,604 people with obesity and existing cardiovascular disease cut major cardiac events by 20%. Cardiovascular outcome data for retatrutide is still being collected in TRIUMPH-Outcomes.²

Do GLP-1 drugs cause muscle loss?

A systematic review found 25-39% of the weight lost can be lean mass rather than fat. Whether that exceeds ordinary dieting is debated, and trials pairing GLP-1s with resistance training or muscle-preserving drugs are underway.⁸

Can GLP-1 drugs slow aging?

One small trial suggests a signal. In 84 adults with HIV, 32 weeks of semaglutide slowed several epigenetic clocks in a post hoc analysis, and a companion pilot reported similar trends. These are biomarkers in a specific population, not lifespan data.⁵⁶⁷⁹

What would change this rating?

Replication of the aging signal in non-HIV populations with clinical endpoints, cardiovascular outcomes for retatrutide from the roughly 10,000-person TRIUMPH-Outcomes trial, and human data on lean-mass preservation.⁵

The incretin revolution represents the most significant pharmacological advance in metabolic medicine since insulin. But the story is more complex than the hype suggests — and the long-term implications remain uncertain.

02Overview

Glucagon-like peptide-1 (GLP-1) receptor agonists and multi-receptor agonists represent a paradigm shift in treating obesity, type 2 diabetes, and cardiometabolic disease. Three agents dominate the current and emerging landscape:

Agent	Generation	Receptors Targeted	Brand Names	Status (2026)
Semaglutide	1st (single)	GLP-1R	Ozempic (T2D), Wegovy (obesity), Rybelsus (oral)	Approved, widely available
Tirzepatide	2nd (dual)	GLP-1R + GIPR	Mounjaro (T2D), Zepbound (obesity)	Approved
Retatrutide	3rd (triple)	GLP-1R + GIPR + GCG-R	LY3437943 (investigational)	Phase 3 — pending approval

Swipe table →

The Core Mechanism

GLP-1 is an incretin hormone — released from intestinal L-cells within minutes of eating. It: - Stimulates glucose-dependent insulin secretion from pancreatic β-cells - Suppresses glucagon release - Slows gastric emptying - Sends satiety signals to the brain (hypothalamus, brainstem) - Reduces food reward signaling in the mesolimbic system

The problem: Endogenous GLP-1 has a half-life of ~2 minutes (rapidly degraded by DPP-4 enzyme). The drugs resist this degradation.

03Mechanisms of Action

Semaglutide (GLP-1 Receptor Agonist)

Modified GLP-1 analog with amino acid substitutions at position 8 (Ala→Aib) and 34 (Lys→Arg)
C-18 fatty di-acid chain enables albumin binding → half-life ~1 week
Receptor potency: Similar to native GLP-1
Primary effects:
Potent appetite suppression via hypothalamic POMC neuron activation
Delayed gastric emptying (contributing to early satiety)
Enhanced insulin secretion (glucose-dependent — low hypoglycemia risk)
Glucagon suppression
Anti-inflammatory effects on vascular endothelium
Direct cardioprotective effects (independent of weight loss)

Tirzepatide (GLP-1/GIP Dual Agonist)

39 amino acid peptide based on GIP backbone with GLP-1 receptor activity
First-in-class dual agonist — simultaneous GLP-1R and GIPR activation
Receptor potency: GLP-1R similar to native; GIPR slightly lower than native GIP
Why dual is better:
GIP receptor activation adds complementary appetite suppression
GIP inhibits hindbrain emesis neurons → reduced nausea vs. GLP-1 alone
GIP enhances adipose tissue lipid buffering → improved insulin sensitivity beyond weight loss alone
GIP may preserve lean mass better than GLP-1 monotherapy

Retatrutide (GLP-1/GIP/Glucagon Triple Agonist)

39 amino acid single peptide from GIP backbone with C20 fatty di-acid moiety
Once-weekly SC injection (half-life ~6 days)
Receptor potency vs. human hormones:
GLP-1R: 2.5× lower potency than native GLP-1
GIPR: 8.9× higher potency than native GIP
GCG-R: 2.9× lower potency than native glucagon
Why add glucagon receptor?
Glucagon agonism increases energy expenditure (thermogenesis)
Reduces hepatic lipid accumulation
Bariatric surgery raises all three hormones simultaneously — triple agonism mimics this more closely
Concern: Glucagon promotes protein catabolism → potential accelerated lean mass loss

04Clinical Evidence

Semaglutide

Weight Loss (STEP Program)

Trial	Population	Dose	Duration	Weight Loss
STEP 1	Obesity/BMI ≥30	2.4 mg weekly	68 weeks	−14.9% vs −2.4% placebo
STEP 2	T2D + overweight	2.4 mg weekly	68 weeks	−9.6% vs −3.4% placebo
STEP 4	Continued vs withdrawal	2.4 mg weekly	68 weeks	−17.4% (continued) vs −5.0% (withdrawn)
STEP 5	2-year extension	2.4 mg weekly	104 weeks	−15.2% sustained

Swipe table →

PMID 33442145 (STEP 1), 33567403 (STEP 2), 35442970 (STEP 4)

Cardiovascular Outcomes (SELECT Trial)

N = 17,604 — overweight/obese + established CVD, no diabetes
20% reduction in MACE (CV death, nonfatal MI, stroke) vs placebo (HR 0.80, p<0.001)
Benefits largely independent of weight loss — direct cardioprotective effect
Waist circumference reduction independently associated with lower CV risk
PMID 37952107

Heart Failure (STEP-HFpEF)

Semaglutide improved heart failure symptoms and physical function in obesity-related HFpEF
Dual benefit: diuretic effect + weight-mediated cardiac unloading

Tirzepatide

Weight Loss (SURMOUNT Program)

Trial	Population	Dose	Duration	Weight Loss
SURMOUNT-1	Obesity (no T2D)	15 mg weekly	72 weeks	−20.9% vs −3.1% placebo
SURMOUNT-2	T2D + obesity	15 mg weekly	72 weeks	−15.7% vs −3.2% placebo
SURMOUNT-3	Continued + lifestyle	15 mg weekly	84 weeks	−26.6% (total)
SURMOUNT-4	Long-term extension	15 mg weekly	88 weeks	−25.3% sustained

Swipe table →

PMID 37111956 (SURMOUNT-1), 37952107 (SURMOUNT-2)

Additional Benefits

Obstructive sleep apnea: Significant improvement (SURMOUNT-OSA)
MASH (fatty liver disease): Resolution in substantial proportion of patients
Heart failure with preserved ejection fraction: Benefit demonstrated (SURPASS program)

Retatrutide

Phase 2 Obesity Trial (48 weeks, N=338)

Outcome	Placebo	Retatrutide 12 mg
Body weight change	−2.1%	−24.2%
≥20% WL achieved	1%	64%
≥30% WL achieved	0%	26%
Triglycerides	+1.4%	−39.9%
LDL cholesterol	−0.3%	−21.7%
Liver fat (substudy)	+0.3%	−82.4%

Swipe table →

No evidence of weight loss plateau at 48 weeks
Greater weight loss in women (−28.5% vs −21.9% in men)
Phase 3 TRIUMPH program ongoing → 28.7% weight loss reported in Phase 3 (2025)

PMID 37952107 (phase 2 data), Lilly press releases 2025 (TRIUMPH-4)

05GLP-1 Drugs and Biological Aging — Landmark 2026 Evidence

First RCT Evidence: Semaglutide Slows Epigenetic Aging

A landmark 2026 study (Corley MJ et al., Nature Communications, May 2026) provides the first randomized, placebo-controlled clinical evidence that a GLP-1 receptor agonist slows biological aging in humans.

Study details: - Design: Phase 2b, double-blind, placebo-controlled RCT — post hoc epigenetic analysis - Population: N=84 adults with HIV-associated lipohypertrophy (NCT04019197) - Intervention: Weekly semaglutide vs placebo for 32 weeks - Assay: DNA methylation-based epigenetic clocks from peripheral blood mononuclear cells (baseline vs Week 32) - PMID: 42156721 · PMC13381876 | DOI: 10.1038/s41467-026-72861-3

Key results (semaglutide vs placebo):

Epigenetic Clock	Result	P-value	Significance
DunedinPACE (pace of aging)	−9% slower biological aging	0.01	↓ Rate of aging
PhenoAge	−4.9 years biological age reduction	0.004	Broad systemic aging
PCGrimAge	−3.1 years (mortality risk-linked)	0.007	↓ All-cause mortality risk markers
GrimAge V2	−2.3 years	0.009	↓ Age-related disease risk markers
OMICmAge	−2.2 years	0.009	Multi-omic systems readout (4th-gen)
RetroAge	−2.2 years	0.030	Retroelement-based epigenetic clock

Swipe table →

System-specific findings: The epigenetic improvements spanned aging measures associated with blood, brain, heart, liver, kidneys, and metabolic health — suggesting broad systemic effects rather than tissue-specific action.

Complementary Pilot Study (npj Aging, 2026)

A second pilot study (Corley et al., npj Aging, 2026) examined semaglutide in HIV+ adults with MASLD (fatty liver disease) over 24 weeks:

42% of participants showed reduced pace of biological aging (DunedinPACE) — and those responders also had greater liver fat reduction
34% showed slowed mortality-risk aging markers (PCGrimAge)
~49% showed increased telomere length markers (PCDNAmTL) — and those responders showed improved physical function (faster walking speed)

DOI: 10.1038/s41514-026-00383-9

Proposed Mechanisms for Aging Effects

Reduced chronic immune activation — GLP-1 drugs lower systemic inflammation, a primary driver of accelerated aging
Visceral/ectopic fat reduction — Fat tissue secretes inflammatory and metabolic signals (adipokines, cytokines) that promote aging; reducing this burden quiets those signals
Cellular reprogramming — Emerging data suggest GLP-1 drugs may reprogram certain cells across organs, explaining the multi-system epigenetic clock improvements (per Corley)
Reduced cellular senescence burden — Lower inflammatory load may reduce SASP-driven paracrine senescence → see Senolytics

Critical Caveats

HIV-specific population: People with HIV experience accelerated aging due to chronic inflammation and antiretroviral therapy. Results may not fully generalize, though the underlying aging biology is shared.
Surrogate endpoints: Epigenetic clocks are biomarkers, not direct clinical outcomes (lifespan, disease incidence). Slowing a clock ≠ extending life.
Short duration: 32 weeks is insufficient to establish durability or long-term effects.
Post hoc analysis: This was a secondary analysis of data from a trial originally designed to study lipohypertrophy, not aging.
Author COI: Corley serves as scientific advisor for TruDiagnostic (a commercial epigenetic testing company).

"We are not saying that semaglutide reverses aging or makes people younger. What we are seeing is a signal that it may slow some of the biological processes associated with aging." — Michael Corley, PhD

Research Implications

The Stein Institute for Research on Aging (UCSD) plans to translate these findings into individualized "aging dashboards" using epigenetic clocks to track biological aging and design personalized therapies. Future trials will need to test: - Whether effects replicate in non-HIV populations - Whether tirzepatide and retatrutide have distinct or enhanced aging effects - Optimal dosing and treatment duration - Whether combining GLP-1 therapy with lifestyle interventions (exercise, dietary restriction, sleep optimization) enhances aging benefits

06Critical Analysis

What the Pharma Industry Doesn't Emphasize

1. Lean Mass Loss — The Sarcopenia Risk ⚠️

Up to 39% of weight lost on GLP-1 therapy may come from lean mass (muscle, bone, organ tissue), not just fat. This is not proportional to total weight loss — it's accelerated.

Systematic review (PMID 38629387): "Semaglutide displays potential for weight loss primarily through fat mass reduction. However, concerns arise from notable reductions in lean mass."
Muscle loss is not benign — sarcopenia is independently associated with mortality, falls, frailty, and metabolic decline
The "Ozempic face" phenomenon reflects more than cosmetic change — it signals global protein catabolism

2. Long-Term Dependency

STEP 4 showed that withdrawal leads to rapid regain (two-thirds of lost weight within 1 year)
This suggests these drugs may need to be taken indefinitely — a $1,000+/month commitment
The business model is clear: chronic medication for chronic condition
Weight regain after discontinuation may leave patients worse off metabolically than baseline due to lost lean mass

3. Unknown Long-Term Effects

GLP-1 receptors are expressed throughout the body: pancreas, brain, heart, kidneys, GI tract, thyroid C-cells
Thyroid C-cell hyperplasia and tumors observed in rodent studies (not confirmed in humans, but monitored)
Pancreatitis risk (rare but serious)
Gastroparesis — chronic delayed gastric emptying that may persist after discontinuation
Effects on gut microbiome are poorly characterized
Impact on mood, depression, and suicidal ideation under FDA investigation (EU investigation initiated 2024)

4. The Reductionist Trap

These drugs address a symptom (excess body weight) without addressing root causes: - Ultra-processed food environment - Insulin resistance from chronic carbohydrate excess - Sedentary lifestyle - Sleep deprivation and circadian disruption - Chronic stress and cortisol dysregulation - Environmental obesogens (endocrine disruptors)

07Doses in studies

Retatrutide (investigational)

Phase 3 trials escalated from 2 mg to 12 mg weekly
Not yet approved — clinical trials only

08Natural GLP-1 Enhancement

Before or alongside pharmaceutical GLP-1 therapy, evidence supports natural approaches:

Intervention	Mechanism	Evidence
Soluble fiber (psyllium, inulin, acacia)	Fermented to SCFAs → stimulates L-cell GLP-1 secretion	★★ Moderate
Berberine (500mg TID)	DPP-4 inhibition + AMPK activation + GLP-1 upregulation	★★ Moderate
Bitter melon	GLP-1 receptor activation + DPP-4 inhibition	★ Emerging
Green tea catechins	DPP-4 inhibition, antioxidant protection of L-cells	★ Emerging
Curcumin	Anti-inflammatory → improved L-cell function	★ Emerging
High-protein meals	Direct stimulation of GLP-1 and PYY release	★★ Moderate
Exercise (especially HIIT)	Acute GLP-1 and GLP-1 sensitization	★★ Moderate
Ginsenosides (Panax ginseng)	GLP-1 secretion enhancement	★ Emerging
Resistant starch	SCFA production → L-cell stimulation	★★ Moderate

Swipe table →

Key insight: Natural approaches cannot match the pharmacological potency of GLP-1 agonists. However, they may reduce the required dose, support lean mass preservation, and address root metabolic dysfunction. The optimal approach combines pharmacotherapy with metabolic optimization.

09Contraindications & Drug Interactions

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
History of pancreatitis
Severe gastroparesis

Relative Contraindications / Caution

History of depression or suicidal ideation (FDA monitoring)
Eating disorders (may mask or worsen)
Pregnancy ( Category X — animal toxicity; stop 2 months before conception)
Gallbladder disease (increased risk of cholelithiasis with rapid weight loss)
Renal impairment (monitor eGFR — mostly reassuring data)
Concurrent insulin or sulfonylureas (hypoglycemia risk — dose adjust)

10Research Gaps & Future Directions

Lean mass preservation — Ongoing trials combining GLP-1 with anti-myostatin antibodies or anabolic agents
Oral GLP-1 agonists — Orforglipron (Lilly, Phase 3) and danuglipron (Pfizer) in development
Quadruple agonists — Preclinical work adding amylin or PYY receptor activity
Combination with senolytics → Senolytics — clearing senescent cells during weight loss
Microbiome interactions — GLP-1 drugs alter gut motility and flora composition; long-term effects unknown
Cancer risk — Long-term surveillance for thyroid, pancreatic, and colorectal effects
Biological aging — The Corley et al. 2026 RCT (PMID 40791720) provides the first human evidence that semaglutide slows epigenetic aging across multiple clocks. This opens an entirely new research frontier: whether GLP-1 drugs are geroscience interventions, not just metabolic drugs. See dedicated section above.

11Retatrutide and Next-Generation GLP-1 Multi-Agonists — Clinical Translation

Overview

Retatrutide (LY3437943) is Eli Lilly's investigational once-weekly triple agonist targeting GLP-1, GIP, and glucagon receptors. As of August 2026, five Phase 3 trials have reported results across the TRIUMPH program. It is the most advanced triple hormone receptor agonist in clinical development, demonstrating weight loss of up to −30.3% at 104 weeks (TRIUMPH-1, 12 mg) — exceeding all approved anti-obesity medications.

Key differentiator: The glucagon receptor agonism component drives hepatic fat oxidation, thermogenesis, and increased energy expenditure through mechanisms not accessible to GLP-1-only or GLP-1/GIP dual agonists. This addresses both sides of the energy balance equation (appetite suppression + energy expenditure).

Mechanism of Action — Triple Receptor Agonism

Receptor	Primary Effects	Clinical Translation
GLP-1R	Central appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion	Reduced caloric intake, glycemic control
GIPR	Enhanced insulin secretion, modulation of lipid storage, improved adipose tissue quality	Synergistic weight loss with GLP-1; reduced GI side effects vs GLP-1 alone
GCGR (Glucagon)	Hepatic fatty acid β-oxidation, thermogenesis, lipolysis, increased energy expenditure	Targets visceral/liver fat; potential lean mass preservation via energy expenditure

Swipe table →

Glucagon receptor specifically: - Upregulates hepatic fatty acid β-oxidation (direct liver fat reduction) - Promotes lipolysis in adipose tissue via G-protein coupled receptor action - Activates brown adipose tissue (BAT) thermogenesis and UCP1-independent futile calcium cycling (SERCA2b-mediated) - Plin5 induction improves coupling between lipid droplet lipolysis and mitochondrial oxidation - Net effect: increased resting energy expenditure beyond what appetite suppression alone achieves

Source: Multi-omic profiling, Diabetol Metab Syndr 2026;18:article 2116. doi 10.1186/s13098-026-02116-0.

Trial Summary

Trial	Phase	Indication	N	Duration	Status	Key Result (12 mg)
TRIUMPH-1	3	Obesity	2,339	80-104 wks	Complete	−28.3% (80w) / −30.3% (104w)
TRIUMPH-2	3	Obesity + T2D	1,152	80 wks	Topline	−20.8% weight; A1C −1.5%
TRIUMPH-3	3	Obesity + CVD	1,949	80 wks	Topline	−22.6% weight
TRIUMPH-4	3	Obesity + Knee OA	445	68 wks	Complete	−28.7% weight; 74-76% pain reduction
TRANSCEND-T2D-1	3	Type 2 Diabetes	—	40 wks	Complete	−16.8% weight; A1C −2.0%
TRIUMPH-5	3	Obesity (vs tirzepatide)	~800	—	Active	Head-to-head body weight primary
TRIUMPH-6	3b	Weight Maintenance	643	—	Active	—
TRIUMPH-Outcomes	3	CV/Renal Outcomes	~10,000	Multi-year	Active	CV composite + kidney endpoints
TRIUMPH-7	3	Obesity + Low Back Pain	586	—	Recruiting	—

Swipe table →

TRIUMPH-1 — Pivotal Obesity Trial (May 2026)

Detail	Value
NCT	NCT05929066
Design	Phase 3, double-blind, placebo-controlled master trial with nested OSA and OA protocols
Participants	2,339 randomized (532 in 104-week extension)
Baseline	Mean ~112.7 kg, BMI 40.0
Doses	—
Duration	80 weeks (extension to 104 weeks for BMI ≥35 subgroup)

Swipe table →

Weight loss at 80 weeks:

Weight loss at 104 weeks (BMI ≥35 extension):

Categorical weight loss at 12 mg: - ≥5% body weight: 100% - ≥10%: ~98% - ≥15%: ~93% - ≥20%: ~75% - ≥25%: 62.5% - ≥30%: 45.3% - ≥35%: 27.2%

Body composition transformation: - 65.3% of participants reached BMI <30 (non-obese category) - 37.5% of class 3 obesity subgroup achieved normal BMI - Waist circumference: −24.1 cm mean reduction - Significant improvements in lipids, blood pressure, hsCRP

Nested basket trials within TRIUMPH-1: - Knee osteoarthritis (n=574): Significant pain reduction and functional improvement - Obstructive sleep apnea (n=243): Marked improvement in apnea-hypopnea index

Sources: Eli Lilly investor release, May 21, 2026. AJMC, May 2026. ADA 2026 Scientific Sessions presentations.

TRIUMPH-2 — Obesity with Type 2 Diabetes (July 2026)

Detail	Value
NCT	NCT05929079
Participants	1,152 (1:1:1:1 to 4/9/12 mg or placebo)

Swipe table →

Results at 12 mg: - Weight loss: −20.8% - HbA1c reduction: −1.5% (9 mg: −1.6%) - Discontinuation due to AE: 3.8% (4 mg), 11.6% (9 mg), 7.7% (12 mg) vs 4.8% placebo

Source: Eli Lilly press release, July 23, 2026.

TRIUMPH-3 — Obesity with Cardiovascular Disease (July 2026)

Detail	Value
Participants	1,949
Duration	80 weeks

Swipe table →

Results at 12 mg: - Weight loss: −22.6% in a population with established cardiovascular disease - Discontinuation due to AE: 9.8% (9 mg), 13.5% (12 mg) vs 4.8% placebo (higher rates in sicker population) - AE profile: GI-dominant; diarrhea (30.1%/24.4% at 9/12 mg vs 8.7% placebo), nausea (21.7%/22.4% vs 5.8%) - Dysesthesia (skin tingling/abnormal sensation): 6.4%/6.4% at 9/12 mg vs 1.3% placebo — a signal unique to retatrutide, possibly related to glucagon receptor activity

Source: Eli Lilly press release, July 23, 2026. TRIUMPH-3 topline.

TRIUMPH-4 — Knee Osteoarthritis (December 2025)

Detail	Value
NCT	NCT05931367
Participants	445
Duration	68 weeks

Swipe table →

Results at 12 mg: - Weight loss: −28.7% - WOMAC pain reduction: 74-76% - Significant physical function gains

Source: Results reported December 2025.

TRANSCEND-T2D-1 — Type 2 Diabetes (March 2026)

Detail	Value
Duration	40 weeks

Swipe table →

Results at 12 mg: - Weight loss: −16.8% - HbA1c reduction: −1.7% to −2.0% - Published simultaneously in The Lancet and presented at ADA 2026

Source: The Lancet, March 2026. ADA 2026 Scientific Sessions.

Phase 2 Obesity — NEJM 2023 (Jastreboff et al.)

48-week trial, 338 participants. −24.2% at 12 mg (−22.8% at 8 mg). This was the trial that established retatrutide as the most potent weight-loss agent in clinical development.

Jastreboff AM et al. N Engl J Med 2023;389:514-526. doi 10.1056/NEJMoa2301972.

Phase 2 T2D — Lancet 2023 (Rosenstock et al.)

36-week trial, 281 participants. HbA1c −2.02% at 12 mg; 67% achieved normoglycemia (HbA1c <5.7%). Weight loss −16.94% at 12 mg.

Rosenstock J et al. The Lancet 2023. PMID 37385280.

Phase 2 Liver Fat Substudy — Nature Medicine 2024

81-86% relative liver fat reduction at higher doses (MRI-PDFF)
78-90% achieved ≥30% liver fat reduction
52-69% achieved liver fat normalization (<5%)
Among the strongest liver fat reductions reported for any pharmacotherapy

Nature Medicine 2024. doi 10.1038/s41591-024-03018-2.

Gastrointestinal Events (Most Common)

AE	4 mg	9 mg	12 mg	Placebo
Nausea	28.6%	38.4%	42.4%	14.8%
Diarrhea	25.2%	34.1%	32.0%	13.5%

Swipe table →

Mostly mild-to-moderate, clustered during dose escalation
Starting at 2 mg (not 4 mg) partially mitigates GI severity

Discontinuation Due to AEs (TRIUMPH-1)

Arm	Discontinuation
Placebo	4.9%
4 mg	4.1%
9 mg	6.9%
12 mg	11.3%

Swipe table →

Cardiac Safety Concerns

Heart rate increase: Dose-dependent, up to +6.7 bpm at 24 weeks, declining thereafter
Cardiac arrhythmias: Mild to moderate (exception: one case of acute pancreatitis in Phase 2)
No increased MACE (major adverse cardiovascular events) observed in Phase 2
TRIUMPH-Outcomes trial (~10,000 participants) is specifically designed to evaluate long-term CV safety at scale
Heart rate increases counteract some benefits of weight loss; requires monitoring

Unique Signal: Dysesthesia

Skin tingling/abnormal sensation reported in TRIUMPH-3 (6.4% at 9/12 mg vs 1.3% placebo)
Possibly related to glucagon receptor activity (not seen with GLP-1/GIP dual agonists)
Clinical significance unclear; under investigation

Body Composition and Muscle Preservation

Retatrutide shows favorable lean mass retention relative to total weight loss in available substudies. The glucagon receptor agonism is hypothesized to support energy expenditure and mitigate sarcopenia through:

Increased thermogenesis and resting energy expenditure
Enhanced hepatic fatty acid β-oxidation (spares muscle protein catabolism)
Adipose tissue metabolic reprogramming toward catabolic state (Plin5 induction, reduced acyl-carnitines)
Improved coupling between lipid droplet lipolysis and mitochondrial oxidation

Human data highlights: - Lean mass loss proportion appears comparable to semaglutide/tirzepatide despite greater absolute weight loss - Body composition substudies from Phase 2/3 are ongoing

Sources: Coskun T et al. Lancet Diabetes Endocrinol 2025 (body composition substudy). Berkovic MC et al. PMC12444289 (muscle preservation review 2025).

Regulatory Pathway and Timeline

BLA filing: Q1 2027 (planned)
TRIUMPH-1, -2, -3: All reported (pivotal registrational data)
Approval window: Late 2027 – 2028
TRIUMPH-5 (head-to-head vs tirzepatide): Ongoing; will determine comparative positioning
TRIUMPH-Outcomes: Multi-year; required for CV safety label claims

Competitive Landscape

Agent	Company	Class	Max Weight Loss	Status
Retatrutide	Lilly	Triple (GLP-1/GIP/GCG)	−30.3%	Phase 3 complete
Tirzepatide	Lilly	Dual (GLP-1/GIP)	−22.5%	Approved (Zepbound)
Semaglutide	Novo Nordisk	GLP-1	−14.9%	Approved (Wegovy)
Orforglipron	Lilly	GLP-1 (small molecule)	−11.2% (ATTAIN-1, 36 mg)	Approved Apr 2026 (Foundayo)
CagriSema	Novo Nordisk	GLP-1 + amylin	−23.9% (REDEFINE-1 DXA sub)	NDA filed Dec 2025; decision late 2026
Mazdutide	Innovent	GLP-1/GCG	Phase 3	Phase 3 (China)
Amycretin	Novo Nordisk	GLP-1/amylin	Phase 2	Phase 2

Swipe table →

Commercial and Clinic Angles

Market disruption: If approved, retatrutide would be the most effective anti-obesity medication by a wide margin
Clinic economics: Potential to shift GLP-1 clinic models toward triple agonist protocols
Muscle preservation protocols: Pairing with resistance training, BPC-157/TB-500, and GlyNAC
Personalization: Metabolic-longevity clinics positioning retatrutide as a precision obesity intervention
MASLD/MASH: 81-86% liver fat reduction could capture the massive MASLD market (25% of global adults)

Evidence Separation Summary

Domain	Human Evidence	Preclinical
Weight loss	Phase 3 (TRIUMPH-1/2/3/4): −20.8% to −30.3%	Strong (multi-species)
Glycemic control (T2D)	Phase 3 (TRANSCEND-T2D-1): A1C −2.0%	Strong
Liver fat (MASLD)	Phase 2: 81-86% reduction	Strong
Muscle preservation	Substudies (ongoing)	Favorable signals
CV outcomes	Ongoing (TRIUMPH-Outcomes, ~10k)	Mixed (heart rate concern)
Knee OA pain	Phase 3 (TRIUMPH-4): 74-76% reduction	—

Swipe table →

Wikilinks

01 - Peptides/GLP-1 Peptides (Semaglutide, Tirzepatide, Retatrutide)
01 - Peptides/GLP-1 Muscle Preservation - Evidence and Protocol Intelligence
11 - Longevity and Anti-Aging/Metformin and Rapamycin
08 - Nutrition and Eating/Metabolic Health and Insulin
09 - Human Biology Optimization/Mitochondrial Health
09 - Human Biology Optimization/Urolithin A - Mitophagy Inducer
01 - Peptides/GlyNAC and Glutathione Precursors - Evidence Taxonomy
01 - Peptides/BPC-157 (Body Protection Compound)
01 - Peptides/TB-500 (Thymosin Beta-4)

What studies and practitioners report

Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.

Trial 2.4 mg/week · Semaglutide (STEP 1) adults with obesity or overweight, n=1961 PMID 33567185
Trial 5–15 mg/week · Tirzepatide (SURMOUNT-1) adults with obesity or overweight, n=2539 PMID 35658024
Trial 1–12 mg/week · Retatrutide (phase 2) adults with obesity, n=338 PMID 37366315
Trial 50 mg/day · Oral semaglutide (OASIS 1) adults with obesity or overweight PMID 37385278

12Connections

Neighborhood · 8 linked entriesOpen full map →

13Sources

PubMed 33442145PubMed 33442145
PubMed 37952107PubMed 37952107
PubMed 37111956PubMed 37111956
NCT04019197NCT04019197
PubMed 42156721PubMed 42156721
PMC13381876PMC13381876
DOI 10.1038/s41467-026-72861-3DOI 10.1038/s41467-026-72861-3
DOI 10.1038/s41514-026-00383-9DOI 10.1038/s41514-026-00383-9
PubMed 38629387PubMed 38629387
PubMed 40791720PubMed 40791720
PMC11848261PMC11848261
PubMed 35442970PubMed 35442970
PubMed 39216535PubMed 39216535
DOI 10.1186/s13098-026-02116-0DOI 10.1186/s13098-026-02116-0
NCT05929066NCT05929066
NCT05929079NCT05929079
NCT05931367NCT05931367
DOI 10.1056/NEJMoa2301972DOI 10.1056/NEJMoa2301972
PubMed 37385280PubMed 37385280
DOI 10.1038/s41591-024-03018-2DOI 10.1038/s41591-024-03018-2
PMC12444289PMC12444289

14Entry history

14 Oct 2026